We are live on ! Find out more
TARO

Taro Pharmaceutical Industries Ltd.

Delisted

TARO was delisted on the 21st of June, 2024.

90 hedge funds and large institutions have $205M invested in Taro Pharmaceutical Industries Ltd. in 2023 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

37% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 27

11% more capital invested

Capital invested by funds: $185M → $205M (+$20.4M)

10% more funds holding

Funds holding: 8290 (+8)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
90
Holders Change
+8
Holders Change %
+9.76%
% of All Funds
1.31%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
13
Increased
37
Reduced
27
Closed
5
Calls
$20K
Puts
Net Calls
+$20K
Net Calls Change
+$20K
Name Holding Trade Value Shares
Change
Change in
Stake
IA
26
Inspire Advisors
Idaho
$572K +$110K +2,987 +28%
AIIMS
27
Analyst IMS Investment Management Services
Israel
$566K
CS
28
Credit Suisse
Switzerland
$548K +$55.1K +1,494 +13%
SO
29
STRS Ohio
Ohio
$547K +$383K +10,400 +385%
MAM
30
Martingale Asset Management
Massachusetts
$519K +$52.7K +1,430 +13%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$463K -$16.9K -458 -4%
SSA
32
Schonfeld Strategic Advisors
New York
$459K +$166K +4,492 +69%
D.E. Shaw & Co
33
D.E. Shaw & Co
New York
$432K +$13.5K +367 +4%
RhumbLine Advisers
34
RhumbLine Advisers
Massachusetts
$391K -$15K -406 -4%
Bank of America
35
Bank of America
North Carolina
$383K -$69.4K -1,882 -17%
Legal & General Group
36
Legal & General Group
United Kingdom
$362K +$14.7K +400 +5%
Allspring Global Investments
37
Allspring Global Investments
North Carolina
$312K +$212K +5,739 +332%
HM
38
Harvest Management
New York
$308K +$10.1K +274 +4%
WG
39
Winton Group
United Kingdom
$307K +$7.3K +198 +3%
Two Sigma Advisers
40
Two Sigma Advisers
New York
$305K -$211K -5,713 -44%
CM
41
Crystalline Management
Canada
$297K +$262K +7,116 New
HF
42
HRT Financial
New York
$294K +$260K +7,045 New
MGP
43
Metis Global Partners
California
$290K
Susquehanna International Group
44
Susquehanna International Group
Pennsylvania
$279K +$246K +6,668 New
UBS AM
45
UBS AM
Illinois
$271K +$36.7K +996 +18%
JP Morgan Chase
46
JP Morgan Chase
New York
$265K -$2.32K -63 -1%
VI
47
Vestcor Inc
New Brunswick, Canada
$246K
Cetera Investment Advisers
48
Cetera Investment Advisers
Illinois
$239K
Goldman Sachs
49
Goldman Sachs
New York
$236K -$445K -12,072 -68%
Verition Fund Management
50
Verition Fund Management
Connecticut
$235K -$2.28M -61,962 -92%

TARO Hedge Fund Activity: Q4 2023 in Review

90 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q4 2023, worth a combined $205M — up 11% from $185M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new TARO positions and 5 closed out — a net gain of 8 holders — while 37 added to existing stakes and 27 trimmed.

The largest buyer was Murchinson, adding an estimated $2.36M. The largest seller was Cowen and Company, exiting entirely with an estimated $2.61M sold.

  • 90 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q4 2023, up from 82 in Q3 2023.
  • Funds reported $205M of Taro Pharmaceutical Industries Ltd. stock for Q4 2023, up 11% quarter-over-quarter.
  • 13 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q4 2023 and 5 closed out, a net change of +8 holders.
  • The largest Taro Pharmaceutical Industries Ltd. buyer in Q4 2023 was Murchinson, an estimated $2.36M added.
  • The largest Taro Pharmaceutical Industries Ltd. seller in Q4 2023 was Cowen and Company, an estimated $2.61M sold.

Based on aggregated 13F filings for Q4 2023.